Investigational drug · Phase 3
Olokizumab
Also called: Artlegia, OKZ
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Polymyalgia Rheumatica, Still Disease, Juvenile Idiopathic Arthritis.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
21
Any phase or sponsor naming "Olokizumab"
First trial start
2023
Mar 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olokizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polymyalgia Rheumatica
- Still Disease
- Juvenile Idiopathic Arthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "Olokizumab" as an intervention, largest first.
R-PharmIndustry
NCT05196477 · 3,087 participants · Start Jul 14, 2021 · Primary completion Aug 29, 2022
Drug: Olokizumab; Standard therapy · For: COVID-19
Sites: Kazan', Russia; Ufa, Russia; Chelyabinsk, Russia · 6 sites in all
- Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisPivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT03120949 · 2,106 participants · Start Jul 4, 2017 · Primary completion Sep 1, 2021
Drug: Olokizumab 64 mg SC q4w; Olokizumab 64 mg SC q2w and 1 more · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Sun City, Arizona · 239 sites in all
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseasePivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT02760407 · 1,648 participants · Start Jun 6, 2016 · Primary completion Aug 2, 2019
Drug: Olokizumab 64mg q4w; Olokizumab 64mg q2w and 2 more · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Sun City, Arizona · 203 sites in all
- Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseasePivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT02760368 · 428 participants · Start May 19, 2016 · Primary completion Aug 2018
Drug: Olokizumab; Placebo · For: Rheumatoid Arthritis
Sites: Minsk, Belarus; Vitebsk, Belarus; Pleven, Bulgaria · 40 sites in all
- Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)Pivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT04380519 · 372 participants · Start Apr 23, 2020 · Primary completion Jul 10, 2020
Drug: RPH-104 80 mg; Olokizumab 64 mg and 1 more · For: COVID-19
Sites: Moscow, Russia; Nizhny Novgorod, Russia; Saint Petersburg, Russia · 16 sites in all
R-Pharm International, LLCIndustry
NCT02760433 · 368 participants · Start Jan 25, 2017 · Primary completion Sep 12, 2019
Drug: Olokizumab; Placebo · For: Rheumatoid Arthritis
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Covina, California · 116 sites in all
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyPivotal-lookingCompleted
UCB PharmaUCB
NCT01242488 · 221 participants · Start Nov 2010 · Primary completion Jun 2012
Drug: CDP6038; CDP6038 and 5 more · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Paradise Valley, Arizona; Scottsdale, Arizona · 82 sites in all
- Study of Efficacy of Different Treatment Regimens of OlokizumabPivotal-lookingStatus unknown
R-PharmIndustry
NCT05187793 · 198 participants · Start Jul 8, 2021 · Primary completion Oct 31, 2022
Drug: Olokizumab; Standard therapy · For: COVID-19
Sites: Moscow, Russia; Voronezh, Russia · 5 sites in all
NCT01296711 · 190 participants · Start Mar 7, 2011 · Primary completion May 1, 2013
Drug: CDP6038 (olokizumab) · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 55 sites in all
- Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesPivotal-lookingRecruiting
R-Pharm International, LLCIndustry
NCT06440746 · 138 participants (planned) · Start Aug 23, 2023 · Primary completion Apr 9, 2027
Drug: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL); SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL · For: Lung Diseases, Interstitial
Sites: Barnaul, Russia; Chelyabinsk, Russia; Gatchina, Russia · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Population PK/PD Modeling and Simulation to Predict the Comparative Long-Term Efficacy of Olokizumab in Rheumatoid Arthritis Patients.
Kosinsky Y, Azarov I, Zhudenkov K, et al. · J Clin Med 2026
- Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).
Fleischmann RM, Strand V, Feist E, et al. · Rheumatol Ther 2026
- Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series.
Meshkov AD, Maslyanskiy AL, Chudinov AL, et al. · Front Med (Lausanne) 2026
- Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial.
Lisitsyna TA, Abramkin AA, Veltishchev DY, et al. · Dokl Biochem Biophys 2026
- Detection of Free and Olokizumab-Bound Interleukin-6 during Anticytokine Therapy.
Pavlova AV, Litvinova AM, Gubernatorova EO, et al. · Biochemistry (Mosc) 2026
- Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.
Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, et al. · Pharmaceuticals (Basel) 2025
Also in development for Polymyalgia Rheumatica
- SPI-62clofutriben, ASP3662Phase 23 trials
Sparrow Pharmaceuticals · Cortisol Excess, Type 2 Diabetes, Polymyalgia Rheumatica
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.